THE National Heart Institute (IJN) has become the first medical centre in Southeast Asia to successfully implant the world’s first dual-chamber leadless pacemaker, the AVEIR™ DR system by Abbott, marking a significant milestone in regional cardiac innovation.
The pioneering procedure, conducted on 27 May, introduces a breakthrough in pacemaker technology that eliminates the need for wires (leads) and surgical pockets, substantially reducing risks of infection, lead dislodgement, and vascular complications.
Eighteen patients have since received the device, which is designed to treat individuals with abnormally slow or irregular heart rhythms.
“This groundbreaking dual-chamber leadless pacemaker will revolutionise care for our current patients and create a significant opportunity to expand the number of people we can serve, including children,” said Datuk Dr Azlan Hussin, IJN’s Senior Consultant Cardiologist and Director of Interventional Electrophysiology & Implantable Devices.
“By eliminating traditional wires, the system significantly reduces complication rates. Long-term data suggest these are typically between one and two per cent, comparable to, or even lower than, rates seen in conventional pacemakers,” he added during a press conference at IJN.
The AVEIR™ DR system comprises two miniaturised devices — each one-tenth the size of traditional pacemakers — that are implanted directly into the right atrium and right ventricle of the heart. The system delivers beat-to-beat synchronisation with real-time pacing analysis, allowing cardiologists to confirm accurate positioning before final deployment.
Dr Azlan noted that the implantation procedure typically takes between 20 minutes to an hour, depending on the patient’s condition.
IJN Chief Executive Officer Professor Datuk Seri Dr Mohamed Ezani Md Taib acknowledged that the cost of the new system is initially higher due to the cutting-edge technology, but stressed that IJN remains committed to affordable specialist care.
“As with any new technology, the initial cost is slightly higher. However, in general, IJN’s charges are significantly lower than those at most private hospitals,” he said.
When asked about the possibility of wider adoption across Malaysia, Dr Mohamed Ezani cautioned that advanced procedures such as this require more than financial investment.
“It’s not just about offering a service. It’s about having the clinical expertise, advanced technology, and the right facilities — something IJN is proud to offer,” he said. “People need to understand this is not a business proposition; it’s about ensuring safety and long-term outcomes for patients.”
He added that IJN’s adoption of the AVEIR™ DR system is a continuation of its mission to drive innovation that delivers tangible health outcomes. “At IJN, innovation isn’t just about introducing new technology, it’s about creating real, meaningful impact,” he said.
The procedure builds upon IJN’s long-standing leadership in leadless pacing technology. In 2018, IJN became the first hospital outside the United States to implant the Micra AV — then the smallest pacemaker in the world.
IJN’s achievement further reinforces Malaysia’s role as a hub for advanced cardiac care in the region, particularly at a time when cardiovascular disease remains a leading cause of mortality nationwide. The institute is expected to lead regional training efforts to expand the safe implementation of leadless pacemakers in neighbouring countries. - June 5, 2025
